ClinicalTrials.gg
Status unknownNCT01507727Updated Jan 11, 2012

Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

A Phase 2/3 interventional study of Tolvaptan and Placebo in Non-hypovolemic Non-acute Hyponatremia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 3 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-01-11.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.

Planned enrollment
3rd of 20
240 · median 55
Started
2012
with 4 others
Phase 2/3
Only one
of the 20
Registered
8th of 20
by date
Lead sponsor
1 of 20
Jiangsu HengRui Medicine Co., Ltd.

Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 3rd largest by planned enrollment, is one of 5 that started in 2012, is the only one in phase 2/3, and was the 8th registered.

Hyponatremia

164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.

Browse Hyponatremia studies →

Open to participants now

None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing tolvaptan in Hyponatremia as a file.
02

Study summary

This drug has been developed to treat Hyponatremia. The primary purpose of this study is to verify the efficacy and safety of seven-day repeated oral administration of tolvaptan at 15, 30, and 60 mg or placebo in patients with Non-hypovolemic Non-acute Hyponatremia secondary to Congestive Heart Failure (CHF), hepatic cirrhosis or Syndrome of Inappropriate Antidiuretic Hormone (SIADH), despite receiving standard therapy. This study is being conducted in China.

03

Conditions studied

  • Non-hypovolemic Non-acute Hyponatremia

Browse trials for

Keywords

  • hyponatremia
  • Non-hypovolemic and Non-acute hyponatremia
  • Tolvaptan
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (for CHF):

  1. Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, or pulmonary congestion.
  2. Non-hypovolemic and Non-acute hyponatremia with a serum sodium \< 135mEq/L before randomization.
  3. Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period.
  4. Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration.
  5. Age:18~80 (when is obtained),male or female.
  6. In-patient subjects.
  7. Informed consent.

Inclusion Criteria (for hepatic cirrhosis):

  1. Patients with hepatic edema.
  2. Non-hypovolemic and non acute hyponatremia with a serum sodium \< 135mEq/L before randomization.
  3. Age:18~65 (when informed consent is obtained),male or female.
  4. In-patient subjects.
  5. Informed consent.

Inclusion Criteria (for SIADH and others):

  1. Patients with SIADH arising from a variety of etiologies.
  2. Non-hypovolemic and non acute hyponatremia with a serum sodium \< 135mEq/L before randomization.
  3. Age:18~80 (when informed consent is obtained),male or female.
  4. In-patient subjects.
  5. Informed consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Drug: Tolvaptan

    Drug: Tolvaptan

  • Placebo comparator
    Drug: Placebo

    Drug: Placebo

Interventions

  • Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.

  • DrugPlacebo

    placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.

06

What researchers measure

Primary outcomes

  1. The change of average daily Area Under the Curve (AUC) of serum sodium by day 4 and 7 comparing with baseline serum sodium level within the double-blind therapy period

    Time frame: 4 and 7 days

Secondary outcomes

  1. Percentage of patients with normalized serum sodium at Day 4

    Time frame: 4 day

  2. Percentage of patients with normalized serum sodium at Day 7

    Time frame: 7 day

  3. Time to first normalization in serum sodium

    Time frame: up to 7 days

  4. Change from baseline in serum sodium at Day 4

    Time frame: 4 day

  5. Change from baseline in serum sodium at Day 7

    Time frame: 7 day

  6. Percentage of patients requiring fluid restriction at any time during the double-blind therapy period of the study

    Time frame: up to 7 days

  7. 24-hour urine output

    Time frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7

  8. Change from baseline in body weight (hypervolemic patients only)

    Time frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7

  9. Fluid balance (hypervolemic patients only)

    Time frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7

  10. The percentage of patients who are designated as treatment failure due to the need for saline infusion, with or without fluid restriction

    Time frame: up to 7 days

  11. For CHF patients, improvement of symptoms and relevant physical examination measures

    Time frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7

  12. For hepatic edema patients, improvement of symptoms and relevant physical examination measures or ultrasound test findings

    Time frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7

07

Study locations

3 of 3 sites recruiting
  • Cardiology, Beijing An Zhen Hospital Affiliated to Capital University of Medical Science
    Beijing, China
    Recruiting
    • Suo · Contact010-64456464
    • Changsheng Ma, PhD · Principal investigator
  • Endocrinology, Beijing Friendship Hospital
    Beijing, China
    Recruiting
    • Liu · Contact010-84205645
    • Wenying Yang, PhD · Principal investigator
  • Hepatology, No. 302 Hospital
    Beijing, China
    Recruiting
    • Yu · Contact010-63879892
    • Fusheng Wang, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2012
First posted
Jan 11, 2012
Start
Jan 2012
Primary completionEst.
Sep 2012
CompletionEst.
Sep 2012
Last update
Jan 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01507727
Collaborators
Beijing 302 Hospital, Beijing Anzhen Hospital, Beijing Friendship Hospital
Responsible party
Sponsor
First posted
Jan 11, 2012
Start date
Jan 2012
Primary completion
Sep 2012 (estimated)
Completion
Sep 2012 (estimated)
Last update
Jan 11, 2012

Study contacts

Fusheng Wang, PhD
Contact
fswang@public.bta.net.cn
Lin Zhu
Contact
acetone_zhulin@yahoo.com.cn
051885475957

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion